Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Exhibit 99.1
POMDOCTOR LIMITED Drive Internet Hospital Growth
Through Strengthened Strategic Partnerships With Pharmaceutical Companies
GUANGZHOU, China, January 16, 2026 /PRNewswire/
- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a leading online medical services platform for
chronic diseases in China, today announced significant progress in its strategic collaboration with leading domestic pharmaceutical companies
to accelerate the growth of its internet hospital business. The Company expects these partnerships become a core component of its long-term
strategy to expand online hospital operations and enhance overall profitability.
Against the backdrop of China’s accelerating
population aging and evolving demographic structure, the domestic internet hospital and online pharmaceutical sales market has expanded
rapidly, demonstrating vast growth potential. According to data from Yaozh.com, a leading pharmaceutical big data service provider in
China, online drug sales in China have grown consistently year over year, rising from approximately RMB 19 billion in 2020 to about RMB
60.8 billion in 2023 and further to RMB 71.8 billion (approximately US$10.3 billion) in 2024, reflecting a compound annual growth rate
(CAGR) of 39.4%.
Leveraging these favorable market dynamics, Pomdoctor
continues to deepen collaborations with pharmaceutical companies to explore emerging opportunities and further strengthen its nationwide
coverage and market presence. Over the past few years, the Company, through its subsidiaries, has entered into sales and purchase agreements
(“Agreements”) with several publicly listed industry leaders and innovative drug makers, including Jiangsu Haosoh Pharmaceutical
Group Co., Ltd., Xiamen Amoytop Biotech Co., Ltd., Shenyang Sinqi Pharmaceutical Co., Ltd., and Eddingpharm (Suzhou) Co., Ltd.
These partnerships enable Pomdoctor to introduce
innovative and patented pharmaceutical products onto its internet hospital platforms, expanding access to advanced treatment options for
partner physicians and patients. At the same time, the collaborations provide pharmaceutical companies with new and efficient sales channels
through internet hospitals. Pursuant to the Agreements, Pomdoctor is entitled to favorable purchase discounts, rebates, and sales incentives
upon the achievement of agreed-upon conditions, including specified sales revenue targets.
Mr. Zhenyang Shi, Chairman and Chief Executive
Officer of Pomdoctor, commented, “China’s rapidly expanding online pharmaceutical sales market offers significant development
opportunities not only for pharmaceutical manufacturers seeking scalable and efficient distribution channels, but also for healthcare
service platform operators. Our flexible collaboration models create win-win outcomes for both Pomdoctor and our pharmaceutical partners
by effectively integrating the strengths of each party in a cost-efficient manner. We are highly optimistic about the long-term potential
of this supply-chain collaboration model, which we view as a key direction in the evolution of modern pharmaceutical distribution and
a catalyst for reshaping the traditional pharmaceutical supply chain.”
He added, “For pharmaceutical companies,
this model enhances channel control, reduces reliance on traditional large distributors, enables more targeted marketing, and improves
cash flow efficiency. For online medical service platforms, direct and stable sourcing from branded manufacturers helps ensure product
quality and pricing advantages, thereby strengthening competitiveness. Most importantly, end users, including pharmacies and patients,
benefit from more competitive pricing, greater supply stability, and a broader selection of products.”
“Looking ahead, we believe this strategic
development model will continue to reduce unnecessary intermediaries while improving efficiency, transparency, and accessibility across
the pharmaceutical distribution value chain. This flattened, digitalized, and patient-centric approach reflects the natural evolution
of the market amid China’s ongoing healthcare reforms. It goes beyond a traditional buyer-seller relationship, representing a deeper
supply chain partnership centered on data sharing, process collaboration, and long-term value co-creation.”
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical
services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market based on the number of contracted
doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers
a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company’s
operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals,
and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value
chain. The Company’s mission is to provide effective prevention and treatment solutions to alleviate patients’ sufferings
from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit
the Company’s website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking
statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current
expectations and projections about future events that the Company believes may affect its financial condition, results of operations,
business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,”
“believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,”
“intends,” “plans,” “will,” “would,” “should,” “could,” “may”
or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect
subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes
that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages
investors to review other factors that may affect its future results in the Company’s filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
